Preliminary results for the year ended 31 december 2024

April 11, 2025 biodexa pharmaceuticals plc (“biodexa” or the “company” or, together with its subsidiaries, the “group”) preliminary results for the year ended 31 december 2024 biodexa pharmaceuticals plc (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces its audited preliminary results for the year ended 31 december 2024. for more information, please contact: biodexa pharmaceuticals plc stephen stamp, ceo, cfo tel: +44 (0)29 2048 0180 www.biodexapharma.com about biodexa biodexa pharmaceuticals plc (listed on nasdaq: bdrx) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs.
BDRX Ratings Summary
BDRX Quant Ranking